Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
37
MRMD Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
17.4%
Day range:
$0.10 - $0.11
52-week range:
$0.07 - $0.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.24x
P/B ratio:
0.64x
Volume:
158.7K
Avg. volume:
422.4K
1-year change:
-66%
Market cap:
$39.6M
Revenue:
$158M
EPS (TTM):
-$0.03
Analysts' Opinion
-
Consensus RatingMariMed has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $0.25, MariMed has an estimated upside of 145.1% from its current price of $0.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.25 representing 100% downside risk from its current price of $0.10.
Fair Value
-
According to the consensus of 2 analysts, MariMed has 145.1% upside to fair value with a price target of $0.25 per share.
MRMD vs. S&P 500
-
Over the past 5 trading days, MariMed has overperformed the S&P 500 by 0.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MariMed does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MariMed has grown year-over-year revenues for 18 quarters straight. In the most recent quarter MariMed reported revenues of $39M.
Earnings Growth
-
MariMed has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MariMed reported earnings per share of -$0.02.
Enterprise value:
105.6M
EV / Invested capital:
--
Price / LTM sales:
0.24x
EV / EBIT:
35.48x
EV / Revenue:
0.67x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-17.94x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
7.63x
Gross Profit (TTM):
$62.9M
Return On Assets:
-5.93%
Net Income Margin (TTM):
-7.7%
Return On Equity:
-18.15%
Return On Invested Capital:
-8.77%
Operating Margin:
-3.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $134M | $148.6M | $158M | $38.9M | $39M | |
| Gross Profit | $64M | $65.9M | $62.9M | $17.3M | $12.7M | |
| Operating Income | $25.1M | $15.2M | $3.5M | $2.7M | -$1.5M | |
| EBITDA | $25.9M | $11.2M | $13.8M | -$5.5M | $1.7M | |
| Diluted EPS | $0.03 | -$0.04 | -$0.03 | -$0.03 | -$0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $21M | $44.6M | $44.1M | $51.4M | $53.5M | |
| Total Assets | $76.4M | $123.2M | $152.2M | $196.1M | $207M | |
| Current Liabilities | $23.2M | $27.2M | $26.5M | $30.9M | $48.7M | |
| Total Liabilities | $68.3M | $86.9M | $94.9M | $126.2M | $147.1M | |
| Total Equity | $8.1M | $36.3M | $57.3M | $69.9M | $59.9M | |
| Total Debt | $36.7M | $18.7M | $29.7M | $66.4M | $75M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $7.3M | $7.9M | $6.8M | $3.2M | -$413K | |
| Cash From Investing | -$26.2M | -$26M | -$17.1M | -$6.3M | -$1.2M | |
| Cash From Financing | -$1M | $23M | $3M | $4.5M | -$893K | |
| Free Cash Flow | -$5.4M | -$12.8M | -$5.9M | -$2.1M | -$1.5M | |
MRMD
Sector
Market Cap
$39.6M
$35.1M
Price % of 52-Week High
32.54%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-66%
-40.62%
Beta (5-Year)
3.147
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-1.14%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.10
200-day SMA
Sell
Level
$0.14
Bollinger Bands (100)
Sell
Level
0.09 - 0.13
Chaikin Money Flow
Buy
Level
59.8M
20-day SMA
Buy
Level
$0.09
Relative Strength Index (RSI14)
Buy
Level
52.36
ADX Line
Buy
Level
25.11
Williams %R
Neutral
Level
-56
50-day SMA
Sell
Level
$0.10
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Sell
Level
-68.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2604)
Sell
CA Score
(Annual)
Level (-0.8696)
Buy
Beneish M-Score
(Annual)
Level (-2.7327)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.8334)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MariMed Inc is a multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Its award-winning portfolio of cannabis brands, including Betty's Eddies, Bubby’s Baked, Vibations, InHouse, and Nature’s Heritage, sets the company apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry.
Stock Forecast FAQ
In the current month, MRMD has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MRMD average analyst price target in the past 3 months is $0.25.
-
Where Will MariMed Stock Be In 1 Year?
According to analysts, the consensus estimate is that MariMed share price will rise to $0.25 per share over the next 12 months.
-
What Do Analysts Say About MariMed?
Analysts are divided on their view about MariMed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MariMed is a Sell and believe this share price will drop from its current level to $0.25.
-
What Is MariMed's Price Target?
The price target for MariMed over the next 1-year time period is forecast to be $0.25 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MRMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MariMed is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRMD?
You can purchase shares of MariMed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MariMed shares.
-
What Is The MariMed Share Price Today?
MariMed was last trading at $0.10 per share. This represents the most recent stock quote for MariMed. Yesterday, MariMed closed at $0.10 per share.
-
How To Buy MariMed Stock Online?
In order to purchase MariMed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
